E31.21 Multiple endocrine neoplasia [MEN] type I

Name of the Condition

• Multiple endocrine neoplasia [MEN] type I (ICD-10 Code: E31.21)

Summary

Multiple endocrine neoplasia [MEN] type I is a hereditary syndrome characterized by the development of tumors in multiple endocrine glands. These tumors may be benign or malignant and commonly affect the parathyroid, pituitary, and pancreatic islet cells. The condition results from genetic mutations that predispose individuals to uncontrolled cell growth in endocrine tissues, leading to hormonal excess or mass effects. Clinical presentation varies based on the glands involved and the specific hormones produced by the tumors.

Causes

MEN type I is caused by germline mutations in the MEN1 gene, which regulates cell growth and tumor suppression. These mutations lead to uncontrolled proliferation in endocrine tissues, resulting in tumor formation. Inheritance is typically autosomal dominant, meaning a single mutated copy of the gene is sufficient to increase risk. The MEN1 gene encodes a protein involved in regulating cell cycle progression and DNA repair, and its dysfunction disrupts normal endocrine gland function.

Risk Factors

• Family history of MEN type I or related endocrine tumors.
• Inherited mutations in the MEN1 gene.
• Prior diagnosis of endocrine neoplasms in close relatives.
• Genetic testing confirming pathogenic variants associated with MEN1.

Symptoms

• Hypercalcemia or kidney stones from parathyroid adenomas.
• Gastrinomas causing peptic ulcers or diarrhea.
• Prolactinomas leading to galactorrhea or amenorrhea.
• Insulinomas resulting in hypoglycemia.
• Nonfunctioning pituitary tumors causing headaches or visual disturbances.

Diagnosis

Diagnosis involves a combination of clinical evaluation, biochemical testing, and genetic testing. Biochemical tests assess hormone levels (e.g., parathyroid hormone, gastrin, prolactin) to identify excess production. Imaging studies (e.g., MRI, CT) may detect tumors in endocrine glands. Genetic testing for MEN1 mutations confirms the diagnosis, especially in individuals with a family history or multiple endocrine tumors. Screening of at-risk family members is recommended.

Treatment Options

Treatment focuses on managing symptoms and removing or controlling tumors. Surgical resection is often used for parathyroid adenomas or pancreatic islet cell tumors. Medications may control hormone excess (e.g., proton pump inhibitors for gastrinomas). For pituitary tumors, dopamine agonists or surgery may be employed. Regular monitoring and surveillance are essential to detect new or recurrent tumors.

Prognosis and Follow-Up

Prognosis depends on the type and extent of tumors, as well as their malignancy. Early detection and treatment improve outcomes. Regular follow-up with endocrinologists and imaging studies are necessary to monitor for new or recurrent tumors. Lifelong surveillance is recommended due to the hereditary nature of the condition.

Complications

• Metastatic spread of malignant tumors.
• Severe hormonal imbalances (e.g., hypercalcemia, hypoglycemia).
• Recurrent tumors requiring repeated interventions.
• Reduced quality of life due to chronic symptoms or treatments.

Lifestyle & Prevention

• Genetic counseling for at-risk individuals and families.
• Regular screening for early detection of tumors.
• Adherence to prescribed medications and follow-up appointments.
• Maintaining a healthy lifestyle to support overall well-being.

When to Seek Professional Help

Seek medical attention if experiencing symptoms such as unexplained weight changes, persistent abdominal pain, headaches, visual disturbances, or signs of hormonal imbalance (e.g., galactorrhea, hypoglycemia). Prompt evaluation is crucial for early diagnosis and management.

Tips for Medical Coders

When coding for MEN type I (E31.21), ensure documentation supports the diagnosis, including genetic testing results or clinical findings of multiple endocrine tumors. Verify that the code is used for confirmed cases, as unspecified or other MEN subtypes may require different codes. Document the specific glands involved and any associated complications to support accurate coding.